This is a phase 1, multicenter, open-label, first-in-human study of YL202 conducted in the United States and China. The study will evaluate the safety and tolerability of YL202 in patients with locally advanced or metastatic epidermal growth factor receptor (EGFR)-mutated NSCLC or hormone receptor (HR)-positive and HER2-negative BC, which have been heavily treated by standard treatment.
Non Small Cell Lung Cancer, Breast Cancer
This is a phase 1, multicenter, open-label, first-in-human study of YL202 conducted in the United States and China. The study will evaluate the safety and tolerability of YL202 in patients with locally advanced or metastatic epidermal growth factor receptor (EGFR)-mutated NSCLC or hormone receptor (HR)-positive and HER2-negative BC, which have been heavily treated by standard treatment.
A Study of YL202 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer and Breast Cancer
-
BRCR Global, Plantation, Florida, United States, 33322
Karmanos Cancer Institute, Detroit, Michigan, United States, 48201
The University of Texas MD Anderson Cancer Center, Houston, Texas, United States, 77030
Next Oncology-Dallas, Irving, Texas, United States, 75039
UT health east Texas HOPE Cancer Center, Tyler, Texas, United States, 75701
Next Oncology-Virginia, Fairfax, Virginia, United States, 22031
Summit Cancer Center, Spokane Valley, Washington, United States, 99216
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
For general information about clinical research, read Learn About Studies.
18 Years to
ALL
No
MediLink Therapeutics (Suzhou) Co., Ltd.,
2026-12